SG11201703574VA - Improved il-6 antibodies - Google Patents
Improved il-6 antibodiesInfo
- Publication number
- SG11201703574VA SG11201703574VA SG11201703574VA SG11201703574VA SG11201703574VA SG 11201703574V A SG11201703574V A SG 11201703574VA SG 11201703574V A SG11201703574V A SG 11201703574VA SG 11201703574V A SG11201703574V A SG 11201703574VA SG 11201703574V A SG11201703574V A SG 11201703574VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- improved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462077105P | 2014-11-07 | 2014-11-07 | |
US201462087448P | 2014-12-04 | 2014-12-04 | |
US201562247705P | 2015-10-28 | 2015-10-28 | |
PCT/US2015/059532 WO2016073890A1 (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703574VA true SG11201703574VA (en) | 2017-05-30 |
Family
ID=54602042
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703574VA SG11201703574VA (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
SG10202103420PA SG10202103420PA (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202103420PA SG10202103420PA (en) | 2014-11-07 | 2015-11-06 | Improved il-6 antibodies |
Country Status (33)
Country | Link |
---|---|
US (2) | US11142571B2 (en) |
EP (3) | EP3215530B9 (en) |
JP (1) | JP6594438B2 (en) |
KR (2) | KR20240023450A (en) |
CN (1) | CN107249631B (en) |
AU (1) | AU2015342882B2 (en) |
BR (1) | BR112017008672A2 (en) |
CA (1) | CA2965689C (en) |
CL (1) | CL2017001135A1 (en) |
CO (1) | CO2017005404A2 (en) |
CR (1) | CR20170231A (en) |
DK (1) | DK3215530T3 (en) |
EA (1) | EA035199B1 (en) |
ES (1) | ES2756275T3 (en) |
HK (1) | HK1244008A1 (en) |
HR (1) | HRP20191945T1 (en) |
HU (1) | HUE046181T2 (en) |
IL (1) | IL251858B (en) |
MA (1) | MA51554A (en) |
MX (2) | MX2017005992A (en) |
MY (1) | MY185114A (en) |
NZ (1) | NZ731090A (en) |
PE (1) | PE20171107A1 (en) |
PH (1) | PH12017500809A1 (en) |
PL (1) | PL3215530T3 (en) |
PT (1) | PT3215530T (en) |
RS (1) | RS59805B1 (en) |
SA (1) | SA517381458B1 (en) |
SG (2) | SG11201703574VA (en) |
SI (1) | SI3215530T1 (en) |
UA (1) | UA122673C2 (en) |
WO (1) | WO2016073890A1 (en) |
ZA (1) | ZA201702985B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
CN108718522A (en) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | IL-6 antagonist formulations and application thereof |
JP2020504105A (en) * | 2016-12-19 | 2020-02-06 | グレンマーク・ファーマシューティカルズ・エスエー | Novel TNFR agonists and uses thereof |
CA3056248A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Optimized antibody compositions for treatment of ocular disorders |
AU2018240375C1 (en) | 2017-03-22 | 2024-02-01 | Ascendis Pharma A/S | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
CN109867723B (en) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | Anti-human IL6 monoclonal antibody and preparation method and application thereof |
IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
TW202144419A (en) | 2020-03-24 | 2021-12-01 | 美商建南德克公司 | Tie2-binding agents and methods of use |
TW202228790A (en) | 2020-10-15 | 2022-08-01 | 美商建南德克公司 | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery |
CN116554298A (en) * | 2022-02-25 | 2023-08-08 | 南京工业大学 | Method for enhancing bacterial frizzled pili and improving secretion production efficiency of human epidermal growth factor |
WO2024088921A1 (en) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Predicting response to il-6 antagonists |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
JP3672306B2 (en) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | Heterodimeric receptor library using phagemids |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
DK1136556T3 (en) | 1991-11-25 | 2005-10-03 | Enzon Inc | Process for the preparation of multivalent antigen-binding proteins |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
FR2734739B1 (en) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | DEVICE FOR MONITORING A BALL MILL |
TW311927B (en) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ES2246069T3 (en) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS. |
US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
EP2154535A1 (en) | 1998-12-10 | 2010-02-17 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
MXPA02001911A (en) | 1999-08-24 | 2003-07-21 | Medarex Inc | Human ctla 4 antibodies and their uses. |
ES2405944T3 (en) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
PT1441589E (en) | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Stable liquid pharmaceutical formulation of igg antibodies |
BR0309844A (en) | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processes for forming a drug delivery device |
AU2003290682A1 (en) * | 2002-11-15 | 2004-06-15 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
SG166768A1 (en) | 2003-12-23 | 2010-12-29 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
KR100864549B1 (en) | 2004-08-04 | 2008-10-20 | 어플라이드 몰리큘라 에볼류션, 인코포레이티드 | Variant fc regions |
AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR20080090484A (en) * | 2005-12-30 | 2008-10-08 | 메르크 파텐트 게엠베하 | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
AU2007224631A1 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against IL-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
CN101600793B (en) | 2006-05-19 | 2013-06-26 | 奥尔德生物制药公司 | Culture method for obtaining a clonal population of antigen-specific b cells |
PL2164514T3 (en) * | 2007-05-21 | 2017-08-31 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
RU2550271C2 (en) | 2007-09-14 | 2015-05-10 | Санофи Пастер Байолоджикс Ко. | Immunogenic composition for treatment or prevention of clostridium difficile, method of obtaining thereof and method of inducing immune response to c difficile |
BRPI0820387A2 (en) | 2007-11-21 | 2015-05-26 | Amgen Inc | Wise binding agents and epitopes |
US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
NZ586828A (en) | 2008-01-15 | 2012-12-21 | Abbott Gmbh & Co Kg | Powdered antibody compositions and methods of making same |
EP2815766B1 (en) | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
PT2324930E (en) | 2008-09-12 | 2012-12-27 | Kdf Co Ltd | Water-spouting device |
US20120005773A1 (en) | 2008-10-01 | 2012-01-05 | Aasen Eric D | Transgenic plants with enhanced agronomic traits |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
KR20110091777A (en) | 2008-11-26 | 2011-08-12 | 글락소 그룹 리미티드 | Polypeptides, antibody variable domains and antagonists |
AU2010208125B2 (en) | 2009-01-29 | 2015-02-12 | Medimmune, Llc | Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
RU2012157167A (en) | 2010-07-12 | 2014-08-20 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Polyfunctional antibody conjugates |
HUE056217T2 (en) | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
CN104768578A (en) | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | Stable, low viscosity antibody formulation |
EP3489258A1 (en) * | 2012-11-08 | 2019-05-29 | Eleven Biotherapeutics, Inc. | Il-6 antagonists and uses thereof |
AU2014286996A1 (en) | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2015
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 SI SI201530995T patent/SI3215530T1/en unknown
- 2015-11-06 MA MA051554A patent/MA51554A/en unknown
- 2015-11-06 PL PL15797538T patent/PL3215530T3/en unknown
- 2015-11-06 MX MX2017005992A patent/MX2017005992A/en unknown
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/en active Active
- 2015-11-06 KR KR1020247004699A patent/KR20240023450A/en not_active Application Discontinuation
- 2015-11-06 RS RS20191447A patent/RS59805B1/en unknown
- 2015-11-06 DK DK15797538T patent/DK3215530T3/en active
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/en active Active
- 2015-11-06 EP EP23189385.0A patent/EP4268843A3/en active Pending
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 NZ NZ731090A patent/NZ731090A/en unknown
- 2015-11-06 UA UAA201705592A patent/UA122673C2/en unknown
- 2015-11-06 CR CR20170231A patent/CR20170231A/en unknown
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/en active Pending
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/en active Active
- 2015-11-06 ES ES15797538T patent/ES2756275T3/en active Active
- 2015-11-06 EA EA201791005A patent/EA035199B1/en not_active IP Right Cessation
- 2015-11-06 PT PT157975384T patent/PT3215530T/en unknown
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/en unknown
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/en active IP Right Grant
- 2015-11-06 BR BR112017008672-7A patent/BR112017008672A2/en active Search and Examination
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/en unknown
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 CA CA2965689A patent/CA2965689C/en active Active
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/en active Application Filing
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-02 PH PH12017500809A patent/PH12017500809A1/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/en unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/en unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/en unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/en unknown
-
2018
- 2018-03-10 HK HK18103370.4A patent/HK1244008A1/en unknown
-
2019
- 2019-10-25 HR HRP20191945TT patent/HRP20191945T1/en unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250583A0 (en) | Anti-tigit antibodies | |
SG11201703403TA (en) | Anti-tim-3 antibodies | |
SG11201703346PA (en) | Anti-tim-3 antibodies | |
HK1244008A1 (en) | Improved il-6 antibodies | |
IL252422A0 (en) | Effector-deficient anti-cd32a antibodies | |
IL250374B (en) | Anti-ceramide antibodies | |
ZA201604640B (en) | Novel anti-netrin-1 antibody | |
GB201410520D0 (en) | Antibody | |
IL248220A0 (en) | Anti-nme antibody | |
HUE054148T2 (en) | Anti-orai1 antibody | |
LT3628731T (en) | Novel anti-presepsin antibody | |
GB201419092D0 (en) | Anti-TIM-3 antibodies | |
GB201419089D0 (en) | Anti-TIM-3 antibodies | |
GB201417614D0 (en) | Antibodies | |
GB201414270D0 (en) | Antibodies | |
GB201405775D0 (en) | Antibodies | |
GB201418776D0 (en) | Antibody | |
GB201401200D0 (en) | Antibodies | |
GB201413745D0 (en) | Antibody | |
GB201411319D0 (en) | Antibody | |
GB201407535D0 (en) | Antibody Drug - Conjugates |